Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Z Domljan

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Arthritis and Rheumatism|November 1, 1995
Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II studyV Mladenovic, Z Domljan, B Rozman, et al.
Arthritis and Rheumatism|December 31, 1998
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonistB Bresnihan, J M Alvaro-Gracia, M Cobby, et al.
Lupus|March 13, 2001
Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluationA J Swaak, H G van den Brink, R J Smeenk, et al.
Rheumatology (Oxford, England)|February 7, 2001
Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT)A J Swaak, H van de Brink, R J Smeenk, et al.
Rheumatology (Oxford, England)|October 27, 1999
Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluationA J Swaak, H G van den Brink, R J Smeenk, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Arthritis and Rheumatism|November 1, 1995
Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II studyV Mladenovic, Z Domljan, B Rozman, et al.
Arthritis and Rheumatism|December 31, 1998
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonistB Bresnihan, J M Alvaro-Gracia, M Cobby, et al.
Lupus|March 13, 2001
Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluationA J Swaak, H G van den Brink, R J Smeenk, et al.
Rheumatology (Oxford, England)|February 7, 2001
Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT)A J Swaak, H van de Brink, R J Smeenk, et al.
Rheumatology (Oxford, England)|October 27, 1999
Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluationA J Swaak, H G van den Brink, R J Smeenk, et al.
Pageof 5